Future Hopes with Immunotherapy Alone or Combinations

Taha Koray ŞAHİNa , Deniz Can GÜVENb
aSultanhanı Dr. Hüseyin Ağır District State Hospital, Clinic of Internal Medicine, Aksaray, Türkiye
bUniversity of Health Sciences Elazığ Fethi Sekin City Hospital, Clinic of Medical Oncology, Elazığ, Türkiye

Şahin TK, Güven DC. Future hopes with immunotherapy alone or combinations. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.141-6.

ABSTRACT
Immune checkpoint inhibitors (ICI) have revolutionized the cancer treatment landscape since their initial approval for melanoma. Although a significant number of patients experience durable responses, the vast majority do not benefit from ICI monotherapy and often develop primary or acquired resistance to therapy. Combination therapies involving ICIs have shown promise in improving outcomes and overcoming resistance. However, combined regimens raise concerns regarding potentially increased toxicity and the possibility of impaired efficacy. This chapter covers ICI-based combination approaches, ongoing and published trials, as well as novel combination strategies, challenges, and future perspectives for cancer treatment. Considering the heterogeneity among patients and cancer types, tailored combination selection may improve the effects of ICI-based combination strategies and tackle the persistent challenge of resistance to treatment.

Keywords: Immunotherapy; immune checkpoint inhibitors; solid tumors; combination therapy; targeted therapy

Referanslar

  1. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044-60. [Crossref]  [PubMed]  [PMC]
  2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. Erratum in: N Engl J Med. 2010;363(13):1290. [Crossref]  [PubMed]  [PMC]
  3. Mooradian MJ, Sullivan RJ. What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma. Oncology (Williston Park). 2019;33(4):141-8.
  4. Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience. 2020;14:1148. [Crossref]  [PubMed]  [PMC]
  5. Guven DC, Sahin TK, Dizdar O, Kilickap S. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. Biomark Med. 2020;14(14):1383-92. [Crossref]  [PubMed]
  6. Guven DC, Sahin TK, Erul E, Rizzo A, Ricci AD, Aksoy S, et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Mol Biosci. 2022;9:1039121. [Crossref]  [PubMed]  [PMC]
  7. Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, et al. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res. 2021;9(1):59. [Crossref]  [PubMed]  [PMC]
  8. Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. Oncoimmunology. 2022;11(1):2077898. [Crossref]  [PubMed]  [PMC]
  9. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al.; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-27. [Crossref]  [PubMed]
  10. Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. Journal of Clinical Oncology. 2023;41(17_suppl):LBA4501. [Crossref]
  11. Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888-98. Erratum in: Lancet Oncol. 2022;23(7):e319. Erratum in: Lancet Oncol. 2022;23(9):e404. [Crossref]  [PubMed]
  12. Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228-38. Erratum in: Lancet Oncol. 2023;24(4):e146. [Crossref]  [PubMed]
  13. Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, et al. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023;8(3):101210. [Crossref]  [PubMed]  [PMC]
  14. Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, et al.; COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023;388(19):1767-78. [Crossref]  [PubMed]  [PMC]
  15. Guven DC, Erul E, Sahin TK, Dizdar O, Yalcin S, Sahin IH. The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncol. 2022. [Crossref]  [PubMed]
  16. Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al.; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22(7):977-90. Erratum in: Lancet Oncol. 2021;22(8):e347. [Crossref]  [PubMed]
  17. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995-1008. [Crossref]  [PubMed]
  18. Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al.; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133-46. [Crossref]  [PubMed]
  19. Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, et al. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021;17(6):637-48. [Crossref]  [PubMed]
  20. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053-61. [Crossref]  [PubMed]
  21. Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2023;24(10):1073-82. [Crossref]  [PubMed]
  22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34. Erratum in: N Engl J Med. 2018;379(22):2185. [Crossref]  [PubMed]  [PMC]
  23. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480-92. Erratum in: Lancet Oncol. 2018;19(12):e668. Erratum in: Lancet Oncol. 2018;19(11):e581. [Crossref]  [PubMed]
  24. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-9. [Crossref]  [PubMed]
  25. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-46. [Crossref]  [PubMed]
  26. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, et al.; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370-85. Erratum in: Lancet Oncol. 2019. Erratum in: Lancet Oncol. 2020;21(6):e304. Erratum in: Lancet Oncol. 2020;21(11):e518. [Crossref]  [PubMed]
  27. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020-31. [Crossref]  [PubMed]
  28. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86. Erratum in: Lancet. 2021;397(10275):670. [Crossref]  [PubMed]
  29. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al.; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. [Crossref]  [PubMed]
  30. Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, et al.; MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):661-74. Erratum in: JAMA Oncol. 2020;6(11):1815. [Crossref]  [PubMed]  [PMC]
  31. Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428-32. [Crossref]  [PubMed]
  32. Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34(4):420-30. [Crossref]  [PubMed]
  33. Park J, Lee JB, Lim MC, Kim BG, Kim JW, Kim S, et al.; KGOG investigators. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D. J Immunother Cancer. 2023;11(10):e007444. [Crossref]  [PubMed]  [PMC]
  34. Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, Trigo J, et al. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clin Cancer Res. 2021;27(8):2168-78. [Crossref]  [PubMed]
  35. Lipson EJ, Tawbi HA, Schadendorf D, Ascierto PA, Matamala L, Gutiérrez EC, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15_suppl):9503. [Crossref]
  36. Vaena DA, Fleming GF, Chmielowski B, Sharma M, Hamilton EP, Sullivan RJ, et al. COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716). J Clin Oncol. 2021;39(15_suppl):2504. [Crossref]
  37. Rodriguez-Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38(15_suppl): 9503. [Crossref]
  38. Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283-95. [Crossref]  [PubMed]
  39. Hamilton E, Shapiro CL, Petrylak D, Boni V, Martin M, Conte GD, et al. Abstract PD3-07: trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. Cancer Res. 2021;81(4_Suppl):PD3-07. [Crossref]
  40. Borghaei H, Besse B, Bardia A, Mazieres J, Popat S, Augustine B, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study. J Clin Oncol. 2020;38(15_suppl):TPS1100-TPS. [Crossref]
  41. Olivier T, Prasad V. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Transl Oncol. 2022;15(1):101248. [Crossref]  [PubMed]  [PMC]
  42. Cho B, Dols M, Cabanillas RR, Baz DV, Pradera JF, Grisanti S, et al. OA05. 04 Sacituzumab Govitecan+ Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study. J Thorac Oncol. 2023;18 Issue 11:S54. [Crossref]
  43. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee J-L, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125-35. [Crossref]  [PubMed]  [PMC]
  44. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-30. [Crossref]  [PubMed]
  45. Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34 Suppl 2:S1340. [Crossref]
  46. Adusumilli PS, Zauderer MG, Rusch VW, O'Cearbhaill R, Zhu A, Ngai D, et al. Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. J Clin Oncol. 2019;37(15_suppl):2511. [Crossref]
  47. Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell. 2019;36(5):471-82. [Crossref]  [PubMed]  [PMC]
  48. Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129(6):904-16. [Crossref]  [PubMed]  [PMC]
  49. Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704-12. [Crossref]  [PubMed]  [PMC]
  50. Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22(1):2. [Crossref]  [PubMed]  [PMC]